Amarin (AMRN) Competitors $0.56 +0.00 (+0.72%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AMRN vs. AVBP, COGT, PAHC, CDMO, RLAY, SANA, AVDL, TYRA, CRON, and SEPNShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Avid Bioservices (CDMO), Relay Therapeutics (RLAY), Sana Biotechnology (SANA), Avadel Pharmaceuticals (AVDL), Tyra Biosciences (TYRA), Cronos Group (CRON), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Amarin vs. ArriVent BioPharma Cogent Biosciences Phibro Animal Health Avid Bioservices Relay Therapeutics Sana Biotechnology Avadel Pharmaceuticals Tyra Biosciences Cronos Group Septerna ArriVent BioPharma (NASDAQ:AVBP) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment. Do insiders and institutionals have more ownership in AVBP or AMRN? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 2.0% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is AVBP or AMRN more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Amarin's net margin of -16.33%. Amarin's return on equity of -7.22% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Amarin -16.33%-7.22%-4.96% Does the MarketBeat Community favor AVBP or AMRN? Amarin received 828 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 73.91% of users gave Amarin an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes16100.00% Underperform VotesNo VotesAmarinOutperform Votes84473.91% Underperform Votes29826.09% Do analysts recommend AVBP or AMRN? ArriVent BioPharma presently has a consensus price target of $36.80, suggesting a potential upside of 50.76%. Given ArriVent BioPharma's higher probable upside, analysts plainly believe ArriVent BioPharma is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Amarin 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, AVBP or AMRN? Amarin has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33MN/AN/AAmarin$306.91M0.75-$59.11M-$0.09-6.20 Does the media refer more to AVBP or AMRN? In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 3 articles in the media. ArriVent BioPharma's average media sentiment score of 0.91 beat Amarin's score of -0.15 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAmarin beats ArriVent BioPharma on 7 of the 12 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.15M$6.23B$5.21B$9.15BDividend YieldN/A2.94%5.13%4.03%P/E Ratio-6.209.5488.0817.36Price / Sales0.75309.511,243.2778.03Price / CashN/A61.4443.7535.97Price / Book0.416.055.314.79Net Income-$59.11M$154.90M$122.62M$225.00M7 Day Performance8.41%-0.32%0.61%2.62%1 Month Performance21.30%0.43%2.56%3.81%1 Year Performance-46.86%3.08%25.79%20.10% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.089 of 5 stars$0.56+0.7%N/A-46.9%$229.15M$306.91M-6.20360AVBPArriVent BioPharma1.3658 of 5 stars$24.83-0.2%$36.80+48.2%N/A$836.70MN/A0.0040Short Interest ↑COGTCogent Biosciences1.5519 of 5 stars$7.46-4.8%$14.83+98.8%+74.9%$824.05MN/A-3.0180Short Interest ↑Positive NewsPAHCPhibro Animal Health4.2269 of 5 stars$20.10+0.2%$20.50+2.0%+88.1%$814.11M$1.05B46.751,860Analyst RevisionCDMOAvid Bioservices2.4075 of 5 stars$12.43+0.2%$12.25-1.4%+99.8%$795.06M$150.45M-5.20320RLAYRelay Therapeutics2.4277 of 5 stars$4.73+6.3%$20.50+333.4%-56.2%$791.72M$10.01M-1.81330SANASana Biotechnology3.0545 of 5 stars$3.46-5.5%$14.25+311.8%-37.5%$772.51MN/A-2.47380AVDLAvadel Pharmaceuticals3.5385 of 5 stars$7.89-0.1%$22.00+178.8%-48.3%$760.30M$138.16M-9.9970TYRATyra Biosciences2.6241 of 5 stars$14.90-2.0%$30.50+104.7%+23.3%$753.99MN/A-9.2520CRONCronos Group2.5796 of 5 stars$1.96-1.0%$3.00+53.1%-0.5%$749.30M$111.23M-15.08450Short Interest ↓News CoveragePositive NewsSEPNSepterna1.6595 of 5 stars$16.80-6.6%$43.67+159.9%N/A$745.97M$981,000.000.00N/A Related Companies and Tools Related Companies ArriVent BioPharma Alternatives Cogent Biosciences Alternatives Phibro Animal Health Alternatives Avid Bioservices Alternatives Relay Therapeutics Alternatives Sana Biotechnology Alternatives Avadel Pharmaceuticals Alternatives Tyra Biosciences Alternatives Cronos Group Alternatives Septerna Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMRN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts